A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail GT
Launched by STRYKER TRAUMA AND EXTREMITIES · Jul 8, 2019
Trial Information
Current as of June 06, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for femur fractures using a device called the Femoral Nail GT. The goal is to see how well this device works compared to standard treatments over a 12-month period. The trial will involve about 50 participants who are 18 years or older and have agreed to take part. Eligible individuals are those with certain types of femur fractures, such as those caused by falls or diseases, and they cannot be enrolled in other clinical studies at the same time.
Participants in the trial can expect to receive standard care for their fractures while using the Femoral Nail GT device. They will have follow-up visits over the next year to monitor their recovery and how well the device is performing. Importantly, this study is designed to help surgeons understand if this new treatment is as effective as existing methods, so it could lead to better options for patients with femur fractures in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is a male or non-pregnant female age 18 years or older at the time of surgery;
- • Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan;
- * Subject is intended to be treated with the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System in accordance with the following legally cleared/ approved Indications for Use:
- Indications for Use approved Outside of Europe include:
- • Fixation of subtrochanteric, intertrochanteric, ipsilateral neck/shaft, comminuted proximal femoral shaft fractures
- • Femoral fixation required as a result of pathological disease
- • Temporary stabilization of fractures of the femoral shaft ranging from the femoral neck to the supracondylar regions of the femur
- • Open and closed femoral fractures
- • Pseudoarthrosis and correction osteotomy
- • Pathologic fractures, impending pathologic fractures and tumor resections
- • Ipsilateral femur fractures
- • Fractures proximal to a total knee arthroplasty
- • Nonunions and malunions
- • Fractures involving osteopenic and osteoporotic bone
- Exclusion Criteria:
- • Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results;
- • Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e. significant circulatory problems, cardiac disease).
About Stryker Trauma And Extremities
Stryker Trauma and Extremities is a leading medical technology company dedicated to advancing innovative solutions for the treatment of trauma and orthopedic conditions. With a strong focus on research and development, Stryker is committed to improving patient outcomes through cutting-edge products and comprehensive clinical trials. The company leverages its expertise in trauma and extremity surgery to deliver safe, effective, and minimally invasive solutions that enhance surgical efficiency and promote rapid recovery. By collaborating with healthcare professionals and leveraging data-driven insights, Stryker Trauma and Extremities aims to set new standards in the field of musculoskeletal care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Falls Church, Virginia, United States
Memphis, Tennessee, United States
Cincinnati, Ohio, United States
Reno, Nevada, United States
Sartell, Minnesota, United States
Patients applied
Trial Officials
Rebecca Gibson
Study Director
rebecca.gibson@stryker.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials